Patents by Inventor Lori Higgs

Lori Higgs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8017109
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: September 13, 2011
    Assignee: Roche Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 8008355
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: August 30, 2011
    Assignee: Roche Madison Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 7985406
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: July 26, 2011
    Assignee: Roche Madison Inc.
    Inventors: Sean D. Monahan, Darren H. Wakefield, David B. Rozema, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Patent number: 7601367
    Abstract: Described is a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: October 13, 2009
    Assignee: Mirus Bio LLC
    Inventors: Sean D. Monahan, David L. Lewis, Hans Herweijer, Jon A. Wolff, James E. Hagstrom, Aaron G. Loomis, Vladimir Trubetskoy, Lori Higgs
  • Patent number: 7501394
    Abstract: We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: March 10, 2009
    Assignee: Roche Madison Inc.
    Inventors: Alexander V. Sokoloff, So Wong, Jon A. Wolff, Sean D. Monahan, James Ludtke, Lori Higgs, Darren H. Wakefield, Magdolna G. SebestyƩn
  • Publication number: 20090023890
    Abstract: The present invention is directed to a class of membrane active polymers useful for cellular delivery of compounds. Conjugation of the described membrane active polymers to targeting, anti-opsonization, and anti-aggregation agents provides polymers suitable for in vivo delivery. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: May 19, 2008
    Publication date: January 22, 2009
    Inventors: Sean D. Monahan, Darren H. Wakefield, David B. Rozema, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080287628
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 20, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080287630
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 20, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080281044
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 13, 2008
    Inventors: Sean D. Monahan, Lori Higgs, Darren H. Wakefield, David B. Rozema, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20080269450
    Abstract: The present invention is directed to membrane active polymers useful for cellular delivery of compounds. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of reversible modification provides for physiologically responsive activity modulation.
    Type: Application
    Filed: June 17, 2008
    Publication date: October 30, 2008
    Inventors: Darren H. Wakefield, David B. Rozema, Sean D. Monahan, Andrei Blokhin, Lori Higgs, Jon A. Wolff, James E. Hagstrom
  • Publication number: 20060154867
    Abstract: We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro.
    Type: Application
    Filed: January 20, 2006
    Publication date: July 13, 2006
    Inventors: Alexander Sokoloff, So Wong, Jon Wolff, Sean Monahan, James Ludtke, Lori Higgs, Darren Wakefield, Magdolna Sebestyen
  • Patent number: 7071163
    Abstract: We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: July 4, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Alexander V. Sokoloff, So Wong, Jon A. Wolff, Sean D. Monahan, James Ludtke, Lori Higgs, Darren Wakefield, Magdolna G. SebestyƩn
  • Publication number: 20050143332
    Abstract: Described is a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell.
    Type: Application
    Filed: May 14, 2004
    Publication date: June 30, 2005
    Inventors: Sean Monahan, David Lewis, Hans Herweijer, Jon Wolff, James Hagstrom, Aaron Loomis, Vladimir Trubetskoy, Lori Higgs
  • Publication number: 20040029826
    Abstract: We describe compounds that bind to and are internalized by hepatocytes. Association of these compounds to other molecules or complexes can be used to target the molecules or complexes to hepatocytes in vivo or in vitro.
    Type: Application
    Filed: August 4, 2003
    Publication date: February 12, 2004
    Inventors: Alexander V. Sokoloff, So Wong, Jon A. Wolff, Sean D. Monahan, James Ludtke, Lori Higgs, Darren Wakefield, Magdolna G. Sebestyen